Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIGLIDE vs BEKYREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRIGLIDE (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) activator. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.
Adjunctive therapy to diet for severe hypertriglyceridemia (Fredrickson types IV and V),Primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb)
Treatment of chronic kidney disease in patients with type 2 diabetes,Reduction of albuminuria in chronic kidney disease
Initial dose: 60 mg (1 tablet) twice daily, gradually increased over 3-7 days to maintenance dose of 120 mg twice daily.
1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.
22-35 hours; prolonged in renal impairment (up to 50 hours).
Terminal elimination half-life: 12 hours (range 10-14 h); prolonged in renal impairment (up to 30 h in Cr Cl <30 m L/min)
Fenofibrate is a prodrug that is rapidly hydrolyzed by esterases to the active metabolite fenofibric acid. Fenofibric acid is conjugated with glucuronic acid and excreted in urine. Major CYP450 involvement is minimal; however, fenofibric acid is a substrate of CYP3A4 and to some extent CYP2C8.
Primarily metabolized by CYP3A4; minor contributions from CYP2C8 and CYP2C9.
Primarily renal (70% as unchanged drug), 20% fecal, <10% biliary.
Renal: 70% (unchanged drug), Biliary/fecal: 30% (metabolites and unchanged drug)
>99% to albumin.
95% bound to albumin and alpha-1-acid glycoprotein
0.11-0.16 L/kg; indicates limited extravascular distribution.
0.8-1.2 L/kg (indicates extensive tissue distribution)
60-70% (oral).
Oral: 60% (range 50-70%; first-pass metabolism reduces bioavailability)
No specific dose adjustment for GFR >10 m L/min; avoid use in patients with GFR <10 m L/min or on dialysis.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended for severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
Contraindicated in Child-Pugh class B and C; use with caution in Child-Pugh class A with dose reduction (e.g., 60 mg twice daily) and monitor closely.
Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg/kg intravenously every 4 weeks; Child-Pugh C: not recommended.
Not approved for pediatric patients; safety and efficacy not established.
Safety and efficacy not established in pediatric patients under 18 years.
Use lowest effective dose; monitor for cardiac and electrolyte disturbances; start at 60 mg twice daily and titrate slowly.
No specific dose adjustment required; consider age-related renal function and comorbidities.
None
None.
Hepatotoxicity: elevations in serum transaminases, rare reports of hepatitis and cirrhosis; monitor hepatic function,Cholelithiasis: increased cholesterol excretion into bile, risk of gallstone formation,Rhabdomyolysis: increased risk in patients with renal impairment, hypothyroidism, or those taking statins or other fibrates,Pancreatitis: observed in patients with severe hypertriglyceridemia,Renal impairment: contraindicated in severe renal disease; dose adjustment needed in mild-to-moderate impairment
Hyperkalemia: Monitor serum potassium regularly; avoid use with strong CYP3A4 inhibitors or potassium supplements.,Acute kidney injury: May occur; assess renal function before initiation.,Adrenal insufficiency: Not studied in patients with adrenal disorders.,Pregnancy: Limited data; avoid use unless benefit outweighs risk.
Severe renal impairment (e GFR < 30 m L/min/1.73 m²),Active liver disease including primary biliary cirrhosis and unexplained persistent liver function abnormalities,Known gallbladder disease,Hypersensitivity to fenofibrate or any component of the formulation,Nursing mothers (due to potential for tumorigenicity in animal studies)
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin),Serum potassium >5.0 m Eq/L at initiation,e GFR <15 m L/min/1.73 m² (not studied),Hypersensitivity to balcinrenone or any excipient
Take with food to enhance bioavailability. Avoid high-fat meals that may exacerbate hypertriglyceridemia. Limit alcohol intake as it can increase triglyceride levels and hepatotoxicity risk. Grapefruit juice has no significant interaction with fenofibrate.
No known food interactions. Avoid grapefruit juice if patient is on concurrent CYP3A4 substrates (though bevacizumab is not metabolized by CYP enzymes). Maintain adequate hydration to reduce risk of constipation, a common side effect.
TRIGLIDE (fenofibrate) is contraindicated in pregnancy due to potential fetal harm. First trimester: no adequate human data; animal studies show embryotoxicity and delayed ossification at doses below human exposure. Second and third trimesters: risk of fetal skeletal abnormalities and growth retardation; use only if maternal benefit outweighs risk.
First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for fetal growth restriction and oligohydramnios.
Fenofibrate is excreted in rat milk; no human data. M/P ratio unknown. Breastfeeding is contraindicated due to potential lipid metabolism disruption in infant and lack of safety data.
No human data on excretion in breast milk. M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in nursing infant.
No dose adjustment guidelines due to contraindication. Pharmacokinetics in pregnancy not studied; no recommended dose changes.
No specific dose adjustments recommended based on pharmacokinetic changes. However, monitor therapeutic effect and adjust dose as needed based on clinical response and tolerability.
TRIGLIDE (fenofibrate) is a fibric acid derivative used as adjunctive therapy to diet for severe hypertriglyceridemia (≥500 mg/d L) to reduce risk of pancreatitis. Monitor renal function before initiation; dose adjustment required if e GFR 30-59 m L/min (starting dose: 48 mg/day). Avoid use if e GFR <30 m L/min or active liver disease. Coadministration with statins increases risk of myopathy/rhabdomyolysis; discontinue if unexplained muscle pain or weakness occurs.
BEKYREE (bevacizumab-awwb) is a biosimilar to bevacizumab. Monitor for hypertension, proteinuria, and bleeding. Discontinue 28 days prior to elective surgery. Avoid use in patients with recent hemoptysis or serious hemorrhage. Infusion reactions may occur; premedicate with antihistamines and acetaminophen as per protocol.
Take with meals to improve absorption and reduce gastrointestinal side effects.,Report unexplained muscle pain, tenderness, or weakness immediately, especially if also taking a statin.,Avoid alcohol consumption as it can worsen triglyceride levels and liver function.,You may need regular blood tests to monitor kidney function, liver enzymes, and lipid levels.,Do not take if you have severe kidney disease or active liver disease.
Tell your doctor if you have a history of bleeding problems, blood clots, or recent surgery.,Avoid taking aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, coughing up blood, or black/tarry stools immediately.,Women of childbearing age must use effective contraception during therapy and for 6 months after last dose.,Do not breastfeed during treatment and for 6 months after the last dose.,Monitor for signs of hypertension (severe headache, blurred vision) and proteinuria (foamy urine).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRIGLIDE vs BEKYREE, answered by our medical review team.
TRIGLIDE is a Fibrate Antilipemic that works by TRIGLIDE (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) activator. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.. BEKYREE is a Antilipemic Agent that works by BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIGLIDE and BEKYREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIGLIDE is: Initial dose: 60 mg (1 tablet) twice daily, gradually increased over 3-7 days to maintenance dose of 120 mg twice daily.. The standard adult dose of BEKYREE is: 1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIGLIDE and BEKYREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIGLIDE is classified as Category C. TRIGLIDE (fenofibrate) is contraindicated in pregnancy due to potential fetal harm. First trimester: no adequate human data; animal studies show embryotoxicity and delayed ossifica. BEKYREE is classified as Category C. First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.